Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026

截至2023年12月31日，Quince Therapeutics報告了7,510萬美元的現金，預計將通過第三階段NEAT收入業績爲主導資產EryDex提供全額資金，併爲2026年可能提交的保密協議做準備

Benzinga · 04/01 07:08

Strong Cash Position Expected to Support Meaningful Clinical Milestone

強勁的現金狀況有望支持有意義的臨床里程碑

Reported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing cash runway to be sufficient to fund the company's capital efficient development plan into 2026.

截至2023年12月31日，報告的現金、現金等價物和短期投資爲7,510萬美元。昆斯預計，其現有的現金流將足以爲該公司2026年的資本效率發展計劃提供資金。

Expect to fully fund lead asset, EryDex, through Phase 3 NEAT topline results and prepare for a potential NDA submission in 2026, assuming positive study results. This includes approximately $20 million for the NEAT study and approximately $15 million in direct trial costs for the open label extension.

假設研究結果良好，預計將通過NEAT的第三階段業績爲主要資產EryDex提供全額資金，併爲2026年可能提交的保密協議做準備。這包括用於NEAT研究的大約2000萬美元以及開放標籤擴展的約1500萬美元的直接試驗費用。

Evaluate potential strategic partnerships to out-license ex-U.S. regional territories to extend operational runway to support potential NDA approval of EryDex, as well as further advance other potential indications and programs discovered using the AIDE platform.

評估潛在的戰略合作伙伴關係，以超越美國前地區領土的許可，以延長運營跑道以支持EryDex的潛在保密協議批准，並進一步推進使用AIDE平台發現的其他潛在適應症和計劃。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息